Peripheral blood progenitor cell (PBPC) mobilization was evaluated in 53 patients receiving the high-dose sequential (HDS) regimen: 27 had non-Hodgkin's lymphoma or Hodgkin's disease, primary refractory or at first relapse, 26 had non-Hodgkin's lymphoma at diagnosis. Mobilization was assessed following either 7 g/m2 cyclophosphamide (48 patients) or 2 g/m2 etoposide, both followed by G-CSF (filgrastim) at 5 microg/kg/d. PBPC mobilization was significantly higher in patients at diagnosis compared to refractory/relapsed patients (median peak values of circulating CFU-GM: 25,209/ml v 4270/ml, P < 0.0001 and CD34+ cells: 286/microl v 47/microl, P < 0.0001). All patients receiving HDS as up-front treatment mobilized enough PBPC for an autograft, often requiring a single leukapheresis; whereas only 15 patients under salvage treatment with HDS were able to complete PBPC autograft. Bone marrow (BM) cells, alone or with PBPC, were needed in six patients, and autograft could not be performed in six patients. Among refractory/relapsed patients, those having a high PBPC mobilization experienced a significantly longer EFS compared to those who had not; autograft completion also significantly enhanced EFS. Thus, the use of an effective mobilizing protocol does not ensure adequate PBPC mobilization in moderately pretreated patients; low mobilization must be considered as an early sign of poor outcome in patients receiving a high-dose salvage programme.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1046/j.1365-2141.1997.3433157.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Radiation Therapy Can Be Safely Incorporated into Pretransplantation Treatment Regimens for Patients with Multiple Myeloma.
Transplant Cell Ther
January 2023
Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Article Synopsis
- The study looked at how radiation therapy (RT) affects collecting certain blood cells from patients with multiple myeloma (MM) who need a stem cell transplant.
- Researchers reviewed medical records of 732 patients who underwent RT between 1999 and 2017, focusing on 223 of them who had RT before collecting blood cells for the transplant.
- They found that the amount of bone marrow treated with RT and the radiation dose didn't seem to impact the number of blood cells that could be collected for the transplant.
Clonal hematopoiesis in patients with stem cell mobilization failure: a nested case-control study.
Blood Adv
April 2023
Department of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Article Synopsis
- Inadequate mobilization of peripheral blood progenitor cells (PBPCs) hampers the success of autologous hematopoietic cell transplantation (auto-HCT), and the study focuses on how clonal hematopoiesis (CH) affects this mobilization.
- The research examined 776 patients, identifying 90 poor mobilizers and 89 controls, revealing that CH was present in 27% of patients, but did not significantly correlate with mobilization failure.
- Notably, mutations in PPM1D and TP53 were more common in poor mobilizers, with a higher incidence of therapy-related myeloid neoplasms (t-MN) in this group, highlighting the need to further explore their
Recombinant human thrombopoietin prior to mobilization chemotherapy facilitates platelet recovery in autologous transplantation in patients with lymphoma: Results of a prospective randomized study.
Chronic Dis Transl Med
September 2021
Department of Medical Oncology, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center, National Clinical Research Center for Cancer, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100021, China.
Background: Chemotherapy plus granulocyte colony-stimulating factor (GCSF) regimen is one of the available approaches to mobilize peripheral blood progenitor cells (PBPCs). It causes thrombocytopenia and delays leukapheresis. This study aimed to evaluate the role of recombinant human thrombopoietin (rhTPO) before mobilization chemotherapy in facilitating leukapheresis in patients with lymphoma.
View Article and Find Full Text PDFEffectiveness of supplemental oral calcium drink in preventing citrate-related adverse effects in peripheral blood progenitor cell collection.
Transfus Apher Sci
August 2021
Department of Hematology and Oncology, Okayama University Hospital, Okayama, Japan.
Peripheral blood progenitor cells (PBPCs) are a predominant graft source in allogeneic hematopoietic cell transplantation. Citrate-induced hypocalcemia remains the most frequent side effect of PBPC apheresis. Although the method for preventing severe adverse events is established, more efficient prophylaxis is required so that volunteer donors can donate PBPCs without pain and anxiety.
View Article and Find Full Text PDFFeasibility and cost analysis of day 4 granulocyte colony-stimulating factor mobilized peripheral blood progenitor cell collection from HLA-matched sibling donors.
Cytotherapy
July 2019
Knight Cancer Institute, Hematology and Medical Oncology, Oregon Health & Science University, Portland, Oregon, USA.
Background: Guidelines recommend treatment with 4-5 days of granulocyte colony-stimulating factor (G-CSF) for optimal donor peripheral blood progenitor cell (PBPC) mobilization followed by day 5 collection. Given that some autologous transplant recipients achieve adequate collection by day 4 and the possibility that some allogeneic donors may maximally mobilize PBPC before day 5, a feasibility study was performed evaluating day 4 allogeneic PBPC collection.
Methods: HLA-matched sibling donors underwent collection on day 4 of G-CSF for peripheral blood (PB) CD34 counts ≥0.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!